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ABSTRACT
Colorectal cancer (CRC) is a life-threatening disease with high prevalence and 
mortality worldwide. The KRAS oncogene is mutated in approximately 40% of CRCs.  
While antibody based EGFR inhibitors (cetuximab and panitumumab) represent a 
major treatment strategy for advanced KRAS wild type (KRAS-WT) CRCs, there still 
remains no effective therapeutic course for advanced KRAS mutant (KRAS-MT) CRC 
patients.  
In this study, we employed a novel and comprehensive approach of gene 
expression connectivity mapping (GECM) to identify candidate compounds to 
target KRAS-MT tumors. We first created a combined KRAS-MT gene signature with 
248 ranked significant genes using 677 CRC clinical samples. A series of 248 sub-
signatures was then created containing an increasing number of the top ranked genes. 
As an input to GECM analysis, each sub-signature was translated into a statistically 
significant therapeutic drugs list, which was finally combined to obtain a single list 
of significant drugs. 
We identify four antihypertensive angiotensin II receptor blockers (ARBs) 
within the top 30 significant drugs indicating that these drugs have a mechanism 
of action that can alter the KRAS-MT CRC oncogenic signaling. A hypergeometric 
test (p-value = 6.57 × 10−6) confirmed that ARBs are significantly enriched in our 
results. These findings support the hypothesis that ARB antihypertensive drugs may 
directly block KRAS signaling resulting in improvement in patient outcome or, through 
a reversion to a KRAS wild-type phenotype, improve the response to anti-EGFR 
treatment. Antihypertensive angiotensin II receptor blockers are therefore worth 
further investigation as potential therapeutic candidates in this difficult category of 
advanced colorectal cancers.
INTRODUCTION
Colorectal cancer (CRC) is a life-threating disease 
with high prevalence and mortality worldwide. According 
to the American Cancer Society, an estimated 134,490 
new CRC cases were diagnosed and 49,190 colon and 
rectum cancer deaths occurred in the U.S. in 2016, making 
CRC the 4th highest in incidence and the 2nd highest in 
mortality of malignant cancers [1]. In the U.K., it has been 
projected that by 2020, there will be 340,000 patients 
living with CRC placing it third among malignant cancer 
types after breast and prostate cancer [2]. CRC is the 
second most common cause of cancer death in the U.K., 
behind lung cancer [3].
The steps involved in CRC development have 
been shown to align with the accumulation of genetic 
mutations, resulting in more aggressive disease at later 
stages, highlighting early detection and intervention as a 
key step in reducing the risk of cancer progression and 
death [3]. With advances in genomics technology the 
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understanding and knowledge of CRC at a molecular 
level is being updated by evaluating gene expression 
profiles of cancerous and healthy samples. The 
identification of genes or proteins associated with CRC 
development as potential biomarkers not only assists the 
early detection of CRC, but also helps to shed light on the 
mechanisms of disease development and progression [4]. 
Although considerable research effort has been devoted 
to the discovery of CRC molecular markers and drugs, 
many published prognostic and predictive markers are 
inconsistent [5, 6]. The Kirsten Ras (KRAS) gene, a 
prominent member of the RAS family, however was 
the first predictive marker approved by the U.S. Food 
and Drug Administration (FDA) for treatment of CRC 
and represents a unique biomarker for epidermal growth 
factor receptor (EGFR)-targeted therapy currently used in 
clinical practice [7].
RAS proteins are a family of related proteins 
sharing very similar GDP/GTP binding domains, and 
play important roles in cell growth, differentiation and 
survival. Characterized by overexpression, activating 
mutations or upstream activation, dysregulation of 
RAS proteins occurs frequently in human cancers. 
While there are many members in this family, the most 
notable ones are HRAS, KRAS and NRAS because of 
their involvement in human cancers [8]. KRAS is found 
to be mutated in a number of human cancers, such as 
CRC, pancreatic and lung cancer. Mutations in the 
KRAS oncogene are common, with a prevalence of 
approximately 40% in CRCs [9]. KRAS has become a 
key target for therapeutic drug development, methods 
to suppress KRAS activity, particularly by disrupting 
KRAS signaling, have been explored in numerous 
studies [10–14]. While there has been substantial effort 
afforded to KRAS directed drug development, currently 
there are no approved drugs to inhibit KRAS for clinical 
use and KRAS mutation has long been considered 
“undruggable” [15]. 
Gene Expression Connectivity Mapping (GECM) 
provides an innovative approach in the discovery of new 
candidate compounds from previously FDA approved 
drugs, which may provide new insights into possible 
treatment strategies for KRAS mutant (KRAS-MT) 
colorectal cancer patients. Connectivity mapping was 
first proposed and developed by Lamb and colleagues 
at the Broad Institute in 2006 [16].  Using a reference 
database, a query signature and a matching algorithm, 
it creates a link between genes, drugs and a biological 
condition [17]. The reference database comprises a large 
collection of data on the differential gene expression 
effects of small molecule compounds applied to cell 
lines. A query gene signature is a list of genes selected 
by the researcher based on experimental results, which 
represents a biological condition such as a disease. To 
measure the similarity between the query signature 
and the differential expression profiles of drugs in the 
reference database, a non-parametric pattern matching 
method is used to calculate a connection score for each 
compound in the reference database indicating its affinity 
to this biological condition. If the gene expression profile 
of a compound in the reference database has the closest 
pattern match but regulates in the opposite direction of 
the query signature, the drug receives the most negative 
score, implying it has the potential to reverse the 
corresponding biological condition [16, 17].  Since the 
initial concept was introduced, research has been done 
to improve the capabilities of connectivity mapping 
[18–22]. The sscMap represented some major efforts 
to refine the scoring scheme and offered noteworthy 
improvements on the connectivity mapping procedure 
[19]. Utilizing the gene expression profiling data released 
by the Broad Institute as the reference database, sscMap 
rebuilt a refined framework of connectivity mapping 
to control false discoveries, through calculations of 
p-value at individual treatment instance level [18]. 
Connectivity mapping is a powerful research tool to 
discover novel drugs for disease and particularly for 
repurposing existing drugs [23–26]. While the first 
version of connectivity map (build 01) included 164 
small molecules and 564 gene expression profiles, 
the Broad Institute recently released the Library of 
Integrated Cellular Signatures (LINCS) transcriptomics 
data via the LINCS Cloud, which contains over 1.3 
million reference profiles including those for over 
20,000 small molecules applied to 77 cell lines [27]. 
While the enormous expansion of data makes this 
research tool more powerful and appealing, screening 
the vast number of significant drugs in the analysis can 
take considerable time. As many of the compounds in 
the reference database are FDA approved, we utilize a 
novel in silico method to pre-screen the drug profiles to 
only include FDA approved drugs as the core collection 
of reference compounds for our main GECM analyses. 
This means that any positive hit has been deemed safe 
as a therapeutic option and could potentially skip phase 
I and enter directly to the phase II clinical trials much 
quicker than non-FDA approved compounds. This could 
save enormous amounts of time and effort in the process 
of drug discovery and development [28–30].
In the current paper, we propose a novel and 
comprehensive procedure for connectivity mapping from 
the creation of a robust query signature to establishing 
new connections between the most significant gene sets 
and the most significant drugs in the database. Using 
KRAS-MT and KRAS wild type (KRAS-WT) expression 
profiles to generate a robust query gene signature for 
comparison against a subset of the LINCS data containing 
1354 FDA approved drugs, this study aims to identify 
new compounds for the treatment of KRAS-MT CRCs 
by making them more amenable to the EGFR-targeted 
therapies that have been effective against KRAS-WT 
tumors.
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RESULTS
Significant genes and their pathway analysis 
To create query gene signatures for connectivity 
mapping, CRC datasets GSE35896, GSE39084 and 
GSE39582 containing microarray expression raw data and 
associated KRAS mutation status were selected from Gene 
Expression Omnibus (GEO). A total of 677 colorectal 
cancer samples were used for our analysis, from which 
a significant gene list of 248 probes was generated by 
combining significant genes from the results of differential 
analysis of the selected datasets (see Supplementary 
Table S1 for the full list of 248 significant gene probes). 
KEGG (Kyoto Encyclopedia of Genes and 
Genomes) pathway analysis was carried out to investigate 
the relationship of significant genes to known pathways 
[31]. Table 1 shows 17 significant pathways (p < 0.05) 
with PPAR signaling pathway, Wnt signaling pathway 
and MAPK signaling pathway being highly enriched. 
Using QIAGEN’s Ingenuity Pathway Analysis to compare 
KRAS-MT and KRAS-WT profiles, our list of 248 
differentially expressed probes, representing 201 unique 
annotated genes, showed upregulation in 133 genes and 
downregulation in 68 genes (see Supplementary Table S2). 
In line with the known role of activating mutations 
in KRAS, cell migration/movement and cell growth/
proliferation were predicted to be highly activated in our 
combined signature (Figure 1). The upstream regulators 
of these functions were predicted to involve the growth 
factors TGFB1, EGF, HGF and IGF1, which have known 
roles in activating these cancer progression pathways 
(Supplementary Table S2).  Using network analysis to 
further interrogate the biological signaling in our combined 
KRAS-MT signature, we observe that the MAPK/ERK 
pathway is highlighted in each of the 3 highest scoring 
networks (Figure 2) giving us confidence that the 
underlying biology represented by the combined signature 
is representative of activation of the KRAS pathway.
Significant drugs
Having firmly established the quality and biological 
relevance of our gene list, GECM was performed in a 
comprehensive manner. From our list of 248 significant 
probes, a series of 248 sub-signatures was created and 
used as inputs to run connectivity mapping.  This series of 
GECM runs returned 248 separate lists of significant drug 
candidates.  After re-combining and prioritizing the drug 
result, 286 drugs are promising candidates to reverse/alter 
the KRAS-MT phenotype. Table 2 shows the top drugs 
with absolute mean score > 0.50 in the result list.
Figure 1: IPA Downstream Effects Analysis: Biological activities associated with the CRC KRAS-MT gene signature. 
Each individual square is a particular biological function or process. Orange squares indicate increases and blue squares decreases in the 
functions. A gray square means no predicted change in that particular function. In this figure, cellular movement and cellular growth/
proliferation are prominently shown to have increased activities. 
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Table 1: Top KEGG pathways associated with the KRAS-MT CRC gene signature
PathwayID Pathway Name P value Pathway Members Overlaps
hsa05412 Arrhythmogenic right ventricular cardiomyopathy 0.0025 67 6
hsa00910 Nitrogen metabolism 0.0039 16 3
hsa00760 Nicotinate and nicotinamide metabolism 0.0056 18 3
hsa03320 PPAR signaling pathway 0.0077 60 5
hsa04610 Complement and coagulation cascades 0.0114 66 5
hsa04310 Wnt signaling pathway 0.0129 122 7
hsa00920 Sulfur metabolism 0.0138 9 2
hsa05217 Basal cell carcinoma 0.0144 46 4
hsa04520 Adherens junction 0.0152 71 5
hsa05146 Amoebiasis 0.0194 103 6
hsa04010 MAPK signaling pathway 0.0211 231 10
hsa05216 Thyroid cancer 0.0211 29 3
hsa04142 Lysosome 0.0238 108 6
hsa00450 Selenocompound metabolism 0.0242 12 2
hsa00350 Tyrosine metabolism 0.0274 32 3
hsa05215 Prostate cancer 0.0306 85 5
hsa04916 Melanogenesis 0.0362 89 5
PPAR signaling, Wnt signaling, and MAPK signaling are among the top enriched pathways that are known to be highly 
relevant to current biological context. Pathway IDs and names are extracted from the KEGG database; Pathway members 
give the number of genes on the Affymetrix U133A microarray platform that are known to be associated with the particular 
pathway.  P-value was obtained from a hypergeometric test assessing the statistical significance of the number of overlap genes 
between the signature and the pathway members present on the microarray.
Figure 2: IPA Network Analysis using the KRAS-MT gene signature. We observe that the MAPK/ERK pathway is highlighted 
in the 3 highest scoring networks. Members of the gene signature are highlighted in red. 
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Trametinib (JTP-74057, GSK1120212) is the drug 
with the highest absolute overall score in the significant 
drug list. The sum score of trametinib across the 248 drug 
lists is –241.5 out of a possible maximum of (+/−)248, 
and the mean score is –0.974. D-cycloserine and lapatinib 
are the second and third overall-ranked drugs, which have 
sum score of –220.3 and –220.0, and mean score of -0.888 
and –0.887, respectively (Table 2).
A number of cancer related drugs are on the 
significant drugs list including some already used for the 
treatment of CRC. Top scoring drug trametinib is used 
for the treatment of unresectable or metastatic melanoma 
with BRAF V600E or V600K mutations. The third-ranked 
drug lapatinib is used as a treatment for solid tumors such 
as breast and lung cancer. Irinotecan (ranked 9) has been 
used as a first-line therapy to treat metastatic colorectal 
cancer. Ponatini (ranked 11) was approved by the FDA 
in 2012 for the treatment of chronic myeloid leukemia 
[32]. Trametinib, lapatinib and ponatini are known signal 
transduction inhibitors. Currently used colorectal cancer 
chemotherapy drugs include etoposide (ranked 67) and 
5-Fluorouracil (ranked 262) [32, 33]. 
Interestingly, we found that antihypertensive 
drugs are highly represented on our significant drugs 
list. There are 7 antihypertensive drugs among the top 
100 drugs, including eprosartan (ranked 12), irbesartan 
(16), losartan (22), olmesartan (28), benazepril (34), 
fenoldopam (64), labetalol (84). Eprosartan, irbesartan, 
losartan, and olmesartan are angiotensin II receptor 
blockers (ARBs), which are within the top 30 of 
significant drugs. Table 3 shows four ARB drugs in the 
result list. There are a total of 8 FDA approved ARB 
drugs being used in the U.S. Apart from azilsartan, 
seven ARB drugs (candesartan, eprosartan, irbesartan, 
losartan, olmesartan, telmisartan and valsartan) are 
included in the LINCS data among the 1354 FDA drugs. 
Four of them were within the top 30 significant drugs in 
the results. A hypergeometric test returned a p-value of 
6.57 × 10−6 suggesting ARB drugs are highly enriched 
among the top drugs. In addition, we found that two 
EGFR inhibitors, lapatinib and lidocaine, are among 
the top 30 GECM predicted drugs.  As there were five 
EGFR inhibitors, afatinib, gefitinib, erlotinib, lapatinib, 
and lidocaine, included in the pool of 1354 FDA drugs, 
Table 2: Top drugs with absolute mean score > 0.50 in the result list
Drug Name Replicates Sumscore Meanscore absMeanscore Rank
Trametinib; JTP-74057; GSK1120212 133 –241.5 –0.974 0.974 1
D-cycloserine 93 –220.3 –0.888 0.888 2
GW-572016; Lapatinib; Tykerb 178 –220.0 –0.887 0.887 3
Rizatriptan 72 –213.2 –0.860 0.860 4
SA59353 24 –192.9 –0.778 0.778 5
Selegiline 37 –192.5 –0.776 0.776 6
Bosentan 55 –191.2 –0.771 0.771 7
Tolterodine 35 –188.9 –0.762 0.762 8
Irinotecan 36 –187.0 –0.754 0.754 9
Budesonide 85 –179.9 –0.725 0.725 10
Ponatinib; AP24534 132 –178.8 –0.721 0.721 11
Eprosartan 45 –177.1 –0.714 0.714 12
Donepezil 73 –175.5 –0.707 0.707 13
Tetrahydrobiopterin 45 –172.8 –0.697 0.697 14
Metaproterenol 44 –171.9 –0.693 0.693 15
Irbesartan 120 –163.0 –0.657 0.657 16
Brimonidine 81 –157.3 –0.634 0.634 17
Caffeine 116 –146.5 –0.591 0.591 18
Meropenem 81 –145.2 –0.586 0.586 19
Lidocaine 73 –133.3 –0.537 0.537 20
Granisetron 10 –131.1 –0.529 0.529 21
Losartan 70 –129.0 –0.520 0.520 22
Nitrazepam 37 –124.5 –0.502 0.502 23
The drugs’ scores across 248 lists were summed and their mean score calculated. This table lists the drug in descending order 
of absolute mean score.  Replicates give the number of reference profiles in the LINCS database for that particular drug.
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a hypergeometric test returned a p-value of 0.0046, 
indicating the enrichment of EGFR inhibitors among the 
top 30 drugs is also statistically significant.  Of these 
5 EGFR inhibitors listed above, afatinib and lapatinib 
are also ERBB2 inhibitors. And they are the only known 
ERBB2 inhibitors included in the LINCS 1354 FDA 
drugs. One of these two, lapatinib made into the top 30 
drugs. Similarly, we also performed the hypergeometric 
test on enrichment of ERBB2 inhibitors and MAP2K1/2 
inhibitors, as these were well known targets of the top 
drug #1 or #3; the results are included in Supplementary 
Table S3.  As can be seen from these results, the 
enrichment of ARB drugs is far more significant than 
the others tested. We consequently focused on the ARB 
drugs as our main findings in this work. 
Contributive genes for the Antihypertensive drugs
In order to discern which signature genes 
contributed to the significant connections between the 
antihypertensive drugs and the KRAS-MT CRC disease 
state, we extracted the LINCS reference gene expression 
profiles for the ARB hypertension drugs detailed in 
Table 3. In analyzing the contributions of the probes in 
the signature towards the negative connection scores of 
these drugs, we obtained lists of 117, 129, 124 and 130 
contributive genes for eprosartan, irbesartan, losartan and 
olmesartan, respectively (see Supplementary Table S4 for 
these four lists of contributive genes).  These gene lists 
were analyzed using Venny to find the overlap between the 
four ARB drugs [34]. As can be seen from Figure 3, there 
Figure 3: Venn diagram of contributive genes of the four ARB drugs. Out of 248 genes, 117, 129, 124 and 130 contributive 
genes were identified for eprosartan, irbesartan, losartan and olmesartan respectively. There are 34 contributive genes common to all four 
ARBs, and 66 contributive genes common to 3 out of 4 ARBs. 
Table 3: Antihypertensive angiotensin II receptor blocker (ARB) drugs in our result list
Drug Names Replicates Indication Mechanism of action Rank
Eprosartan 45 Hypertension, diabetic nephropathy, congestive heart failure
angiotensin II receptor blocker (ARB): 
inhibits the binding of angiotensin II to 
angiotensin II type 1 (AT1) receptor
12
Irbesartan 120 Hypertension, diabetic nephropathy, congestive heart failure
angiotensin II receptor blocker (ARB): 
inhibits the binding of angiotensin II to  its 
type 1 (AT1) receptor
16
Losartan 70
Hypertension, diabetic nephropathy, 
congestive heart failure, myocardial 
infarction
angiotensin II receptor blocker (ARB): 
inhibits the binding of angiotensin II to  its 
type 1 (AT1) receptor
22
Olmesartan 37 Hypertension
angiotensin II receptor blocker (ARB): 
inhibits the binding of angiotensin II to  its 
type 1 (AT1) receptor
28
We have checked the pharmacodynamics of the top drugs in the ranked list. ARB drugs are found to be prominently represented 
among the top drugs of the list.  This is statistically very significant with a p-value of 6.57 × 10−6 (hypergeometric test).
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are 34 genes common to all four drugs, with a further 66 
present in at least three lists out of the four (see Table 4 for 
details of the common 34 genes).
Using Ingenuity Pathway Analysis (IPA) we carried 
out phenotype and network predictions based on the 
34 common genes contributing to the four ARB anti-
hypertension drugs. The common phenotypic pathway 
which these drugs are predicted to perturb is cell growth/
proliferation, which alongside cell migration was the most 
activated pathway represented in the KRAS-MT tumor 
signature (Figure 4). Further detailed analysis of these 
34 genes contributing to the anti-hypertension drugs, 
highlights the MAP Kinase specific nature of their action 
(Figure 5), underpinning their KRAS-directed mechanism 
of action.
Validation of the GECM approach against drug 
screen sensitivity data from independent studies
To validate the GECM approach proposed in this 
paper, we conducted an extensive in silico validation 
exercise to demonstrate the power and accuracy of our 
prediction against drug screen sensitivity data from 
independent studies. This was possible thanks to several 
recent studies, which screened large collections of 
genetically characterized human cancer cell lines against 
hundreds of compounds [35–39]. For our purpose of 
validating the GECM approach, we were particularly 
interested in the cell viability reduction data for our top 
candidate compounds in colorectal cancer cell lines with and 
without KRAS mutation. The Seashore-Ludlow study and 
the Garnett study were chosen for this validation exercise.  
The Seashore-Ludlow 2015 study [35] screened 
481 compounds, 286 of which were also included in 
the LINCS compounds collection. This common set 
of compounds allowed us to validate the prediction of 
GECM. Using the LINCS reference gene expression 
profiles for these 286 compounds as a core database, 
we performed connectivity mapping analysis using the 
same KRAS-MT gene signature. This gave a list of top 
compounds that could potentially benefit the KRAS-
MT CRCs. Then we examined the sensitivity of all the 
CRC cell lines in the Seashore-Ludlow study to these top 
compounds. 
We extracted the drug screening data for the cell 
lines that were labelled as colorectal cancer (CRC), with 
the term “large intestine carcinoma”. In total, 49 cell 
lines were identified as CRC. Of these 49 CRC cell lines, 
25 were KRAS-WT and 24 were KRAS-MT. We then 
compared the sensitivity of GECM predicted compounds 
Figure 4: Phenotypical function analysis (34 genes). The results show cell migration, cell growth/proliferation were highly activated 
(this is same as the activated pathways in the original KRAS-MT CRC signature, see Figure 1), indicating ARBs target cell migration, cell 
growth/proliferation.
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in the KRAS-MT versus KRAS-WT CRC cell lines. 
Among the top 20 GECM predicted drugs (with absolute 
mean score > 0.25), 16 of them turned out to be more 
sensitive in KRAS-MT CRC cell lines than in KRAS-WT 
CRC cell lines. Although the differences in sensitivity were 
relatively small, the accuracy in predicting the direction 
of action was 80%. Supplementary Table S5 provides 
the details of these 20 compounds and the corresponding 
sensitivity data, area under concentration-response-curve 
(AUC), as obtained from   the Seashore-Ludlow study. 
Similar to the analysis performed against the 
Seashore-Ludlow study above, we investigated a second 
Table 4: The list of 34 contributive genes common to the 4 ARB drugs
Gene Symbol Description Regulation 
ABHD2 Abhydrolase Domain Containing 2 Up
APOBEC1 Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide 1 Up
BCL2L14 Bcl2-Like 14 (Apoptosis Facilitator) Up
C3orf52 Chromosome 3 Open Reading Frame 52 Up
CD44 Cd44 Molecule (Indian Blood Group) Up
CD55 Cd55 Molecule, Decay Accelerating Factor For Complement (Cromer Blood Group) Up
CKAP4 Cytoskeleton-Associated Protein 4 Up
CTSE Cathepsin E Up
DSG3 Desmoglein 3 Up
DUSP4 Dual Specificity Phosphatase 4 Up
EPS8L1 Eps8-Like 1 Up
HGD Homogentisate 1,2-Dioxygenase Up
HOXB3 Homeobox B3 Up
HOXB5 Homeobox B5 Up
HOXB6 Homeobox B6 Up
HOXB7 Homeobox B7 Up
HOXB9 Homeobox B9 Up
IL33 Interleukin 33 Up
KIAA1199 Cell Migration Inducing Protein, Hyaluronan Binding [CEMIP] Up
KRT6B Keratin 6B Up
LYZ Lysozyme Up
MAP3K5 Mitogen-Activated Protein Kinase Kinase Kinase 5 Up
ME1 Malic Enzyme 1, NADP(+)-Dependent, Cytosolic Up
MSX2 Msh Homeobox 2 Up
MUC2 Mucin 2, Oligomeric Mucus/Gel-Forming Up
NAAA N-Acylethanolamine Acid Amidase Down
RBMS1 RNA Binding Motif, Single Stranded Interacting Protein 1 Down
REEP1 Receptor Accessory Protein 1 Down
RGNEF Rho Guanine Nucleotide Exchange Factor (GEF) 28 [ARHGEF28] Up
SCRN1 Secernin 1 Down
TFF1 Trefoil Factor 1 Up
TFF3 Trefoil Factor 3 (Intestinal) Up
TRIM16 Tripartite Motif Containing 16 Up
ZBTB10 Zinc Finger And Btb Domain Containing 10 Down
The signed ranks of signature genes in the reference profiles of 4 ARB drugs were analyzed in conjunction with their regulation 
directions. Genes that make a strong and consistent contribution to the inverse connection scores are selected for each of the 
4 ARB drugs. The 4 lists of contributive genes were overlapped and the common set of 34 is itemized here.  Their directions 
of regulation in the signature are indicated in the last column.
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study from which the KRAS mutation status of assayed 
cell lines can be readily retrieved. The Garnett 2012 
study [38] screened 131 compounds in 639 human tumor 
cell lines with IC50 data provided as Supplementary 
Information. Of these 131 Garnett compounds, 121 were 
included in the LINCS compound collection. We thus 
extracted all the LINCS reference gene expression profiles 
for these 121 Garnett compounds and used them as a 
core database for gene expression connectivity mapping 
with the KRAS-MT gene signature. Again, a list of top 
candidate drugs predicted to be effective in KRAS-MT 
CRCs was returned. Following the same approach, we 
extracted the drug sensitivity data of these top candidate 
drugs in all the 34 CRC cell lines from the Garnett study. 
Sixteen of these CRC cell lines were KRAS-WT and 18 
were KRAS-MT. One KRAS-WT cell line was a genetic 
outlier and discarded because it had a copy number > 8, 
unlike all the other 15 KRAS-WT cell lines. Among the 
13 GECM predicted compounds (with absolute mean 
score > 0.25), 10 of them turned out to be more sensitive 
in KRAS-MT CRC cell lines than in the KRAS-WT CRC 
cell lines. In this case, the accuracy of GECM prediction 
on the drug’s direction of action in the CRC cell lines 
is 77%. Supplementary Table S6 provides the details of 
these 13 compounds and the corresponding drug screen 
sensitivity IC50 data as obtained from the Garnett study. 
Taking two independent validation data sets 
together, the 77% ~ 80% agreement in the direction of 
action between GECM predictions and cell line drug 
screen experiments is remarkable.  It should be noted that 
no known ARB drugs were screened in either study above, 
so we could not compare ARBs sensitivity in the cell lines 
directly. However, the 77% ~ 80% success rate provided 
strong evidence that the GECM approach described in 
this paper is working well. This in turn can provide us 
with high confidence in our findings that ARBs could be 
potential drugs used in KRAS-MT CRCs. 
We note that in the two independent validation 
datasets described above, the compounds used in the 
GECM analysis were not limited to FDA approved drugs. 
Consequently, some non-FDA approved compounds 
were also returned by GECM as potentially effective in 
Figure 5: The signaling and interaction network associated with the 34 common contributive genes for the four ARB 
drugs. MAPK/ERK signaling is seen at the heart of this network. Red nodes represent genes up-regulated, green nodes down-regulated, 
and gray nodes not among the 34 common genes.
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treating KRAS-MT CRCs. Here we only mention the top 
hit, selumetinib, from the Seashore-Ludlow compound 
collection, and PD-0325901, from the Garnett compound 
collection. Both were more sensitive in KRAS-MT than in 
KRAS-WT CRC cell lines. Selumetinib, in combination 
with some existing cancer drugs (eg, docetaxel, erlotinib, 
cetuximab), is being/has been investigated in clinical 
trials for treating KRAS-MT solid tumors including non-
small-cell lung cancer (NSCLC) [40, 41] and CRC [42]. 
The experimental drug PD-0325901, too, in combination 
with an approved drug palbociclib, is being investigated in a 
clinical trial as a possible treatment for cancers with KRAS 
mutations, particularly for those which started in the lung 
(https://clinicaltrials.gov/show/NCT02022982). Details of 
other GECM hits using the Seashore-Ludlow and the Garnett 
compound collections can be found in the corresponding 
Supplementary Files for these two validation sets. 
DISCUSSION
To our knowledge this is the first study using 
clinical data and connectivity mapping to identify 
candidate compounds for KRAS-MT CRC. We proposed 
a comprehensive procedure for connectivity mapping with 
the aims of getting quality signatures and obtaining robust 
and meaningful drug results.
We performed differential expression analysis 
on 677 samples across 3 colorectal cancer datasets, 
from which 248 gene probes were identified as being 
differentially expressed between KRAS-MT and KRAS-
WT. These 248 gene probes were mapped to known 
pathways to determine if any signaling networks are 
overrepresented in the gene signature identified. As a 
result, PPAR signaling pathway, Wnt signaling pathway 
and MAPK signaling pathway were identified as among 
the most prominent pathways represented in our KRAS-
MT gene signature.
Peroxisome proliferator-activated receptors (PPARs) 
are nuclear hormone receptors playing essential roles in 
the regulation of cellular differentiation, development, 
metabolism and tumorigenesis [43]. There are three known 
types of PPARs, including alpha, gamma and delta (beta). 
PPAR gamma is involved in the regulation of numerous 
genes regulating cell differentiation and apoptosis [44]. 
As such, PPAR gamma has been implicated in various 
diseases including cancers [43]. PPARs can either be tumor 
suppressors or accelerators (oncogenes), and are therefore 
potential candidates as drug targets for cancer prevention 
and treatment [45]. PPAR gamma activators show promise 
as a future cancer therapeutic [46].  The growth and 
differentiation of colon cancer cells can be modulated 
through PPAR gamma where loss-of-function mutations 
in PPAR gamma have been shown to be associated with 
colon cancer, suggesting that activation of this receptor 
might have an anticancer effect in this disease [47, 48]. 
Wnt signaling pathways regulate cell fate 
determination, cell migration, cell polarity, neural patterning 
and organogenesis, and play a critical role in embryonic 
development [49]. Wnt signaling pathways include the 
canonical Wnt pathway, the non-canonical planar cell polarity 
pathway and the non-canonical Wnt/calcium pathway. Wnt 
signaling has had an association with cancer since its initial 
discovery. Research found that mutation of the adenomatous 
polyposis coli gene (APC), which in turn activates the Wnt 
signaling pathway, is a vital event in the development of 
colon cancer. Non-canonical Wnt and other distinct pathways 
in the tumor micro-environment interact with the canonical 
Wnt pathway and influence colon cancer progression. These 
non-APC aspects are considered linked to the development 
of potential treatment for colorectal cancer [50].
Mitogen-activated protein kinase (MAPK, also 
known as ERK) regulates various cellular functions, 
including proliferation, gene expression, differentiation, 
mitosis, cell survival, and apoptosis [51]. A defect in the 
MAPK/ERK pathways may lead to uncontrolled growth 
of cells, which is necessary for the development of all 
cancers. In cancer, RAS and BRAF are among the most 
frequently mutated members of this extracellular signal-
regulated kinase pathway. Therefore, members of MAPK/
ERK pathways, particularly RAS and BRAF are potential 
drug targets, the inhibition of which is a strategy for 
developing cancer treatment.
The results from KEGG Pathway analysis 
indicate that the identified significant genes are strongly 
correlated to PPAR, Wnt, MAPK signaling pathways. 
These pathways are clearly involved in colorectal cancer 
progression and development, and are well recognized 
as potential therapeutic targets. This also demonstrated 
that our results from differential analysis provided highly 
accurate gene signatures for KRAS-MT colorectal cancers.
GECM identified 286 significant drugs. A number 
of colon cancer specific therapeutic agents were retrieved 
from the drug list providing evidence of credibility in 
the approach.   For example, irinotecan, etoposide and 
5-fluorouracil were retrieved as drugs relevant to the CRC 
signature.  The top three significant drugs were trametinib, 
D-cycloserine and lapatinib, two of which are known 
cancer therapies and one is a novel discovery.
Trametinib is a MEK inhibitor with anti-cancer 
activity, as an FDA approved cancer drug used for 
the treatment of BRAF mutant melanoma. Trametinib 
decreases cell proliferation and increases cell apoptosis. 
Research has found that trametinib exhibits a synergistic 
effect when combined with 5-fluorouracil, oxaliplatin 
or SN-38; these findings suggest that trametinib is a 
useful therapeutic drug for colorectal cancer [52], again 
validating clinical utility of the approach used in this 
current study. This is also consistent with the finding 
that KRAS mutation may be a good biomarker of MEK 
inhibitor sensitivity for treating colorectal cancer [53]. 
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GW-572016 (Lapatinib/Tykerb) is a small-molecule 
inhibitor of the epidermal growth factor receptor (ErbB1, 
EGFR) and ErbB2(HER2/neu) tyrosine kinases. It may 
seem a bit surprising that lapatinib, being an EGFR 
inhibitor, appears as one of the top hits of GECM 
results given that the EGFR inhibitors cetuximab and 
panitumumab are not very effective in treating KRAS-
MT advanced CRCs. On the other hand, it is worth noting 
that the ineffectiveness of those two antibody based EGFR 
inhibitors does not necessarily mean that other types of 
EGFR inhibitors, eg. small molecule based ones such as 
lapatinib, should all be ineffective. This FDA approved 
drug was developed by GlaxoSmithKline to treat solid 
tumors like breast and lung cancer. There is a good 
amount of evidence to suggest that this hit does make 
a lot of sense. For example, lapatinib plus trametinib in 
KRAS-MT malignancies is now undergoing a clinical 
trial (NCT02230553), a phase I/II study with lapatinib 
plus trametinib in patients with metastatic KRAS-MT 
colorectal, non-small cell lung and pancreatic cancer [54]. 
We note here that the two drugs used in this clinical trial, 
trametinib and lapatinib, happen to be our #1 and #3 top 
drugs, respectively. Research has found that inhibition 
of HER2/neu activity may help in treating metastatic 
colorectal cancer and tumors with mutant KRAS. As 
lapatinib sensitizes colon cancer cells to EGFR inhibitors 
or fluoropyrimidines, the combination of lapatinib with 
standard chemotherapy has been suggested as a new 
strategy for the treatment of metastatic colorectal cancer 
[55, 56].
D-cycloserine (cycloserine), the second highest 
scoring drug, is a novel discovery. Cycloserine is an 
approved antibiotic drug produced by Streptomyces 
garyphalus used to treat Mycobacterium avium complex 
(MAC). Together with up to 5 other drugs, it is also used 
to treat tuberculosis. There is no evidence in the literature 
that cycloserine has been investigated in the treatment of 
colorectal cancer.
In addition to reviewing the drugs individually, 
it was important to assess whether any drug clusters 
are overrepresented on the list. This method is similar 
to pathway or gene set enrichment analysis, but here it 
is applied to drug groups with similar indications. To 
our knowledge, this is the first time drug enrichment 
methods have been employed to interpret and prioritize 
the predictions from connectivity mapping. Interestingly, 
we found 7 hypertension drugs among the top 100 drugs, 
including four antihypertensive angiotensin II receptor 
blockers (ARBs): eprosartan, irbesartan, losartan and 
olmesartan within the top 30. 
Hypertension (high blood pressure/arterial 
hypertension) is a chronic medical condition in which the 
blood pressure in the arteries is persistently elevated. High 
blood pressure is a known risk factor for cardiovascular 
disease, the most attributable cause of cardiovascular 
death [57]. Compared to normal blood pressure, high 
blood pressure is linked to higher risks of cancer 
incidence (e.g. oral, colorectal, lung and bladder cancers) 
in men and cancer death in men and women [58–60]. 
As antihypertensive medicines, angiotensin-converting-
enzyme inhibitors (ACEIs) and antihypertensive 
angiotensin receptor blockers (ARBs) target the renin-
angiotensin system that has also been found to be involved 
in carcinogenesis by regulating cell proliferation and 
tumor growth [61]. Renin–angiotensin system inhibitors 
ACEIs/ARBs might influence tumor angiogenesis by 
reducing vascular endothelial growth factor expression 
and induce apoptosis in cancer cells [62]. A systematic 
review by researchers indicated that ACEIs/ARBs might 
be associated with a reduced risk of CRC and precancerous 
lesion. Anti-angiotensin treatments have been found to 
suppress liver metastasis of colon cancer cells [63]. In 
addition, work by Makar et al found that long term and high 
dose use of angiotensin converting enzyme inhibitor (ACEI) 
and/or angiotensin receptor blockers (ARBs) may be 
associated with a decreased incidence of colorectal cancer 
[64]. Furthermore, Engineer et al have found that exposure 
to angiotensin-converting enzyme inhibitors (ACEIs)/
angiotensin receptor blockers (ARBs) and β-adrenoceptor 
blockers (β-blockers) is associated with improved survival 
and decreased tumor progression and hospitalizations in 
patients with advanced colon cancer [65]. 
For reasons of efficacy and cost, calcium channel 
blockers and thiazide-type diuretics are chosen as first-
line treatments for hypertension, but ACE inhibitors are 
increasingly being used. For patients under the age of 
55 who cannot tolerate ACE inhibitors, an angiotensin II 
receptor antagonist is recommended as first-line treatment. 
As antihypertensive medicines, angiotensin-converting-
enzyme inhibitors (ACEIs) and antihypertensive angiotensin 
receptor blockers (ARBs) target the renin-angiotensin 
system in different ways. ACEIs block enzyme activities of 
converting the chemical angiotensin I into angiotensin II in 
the blood. In contrast, ARBs do not prevent the formation of 
angiotensin II, but instead block receptors of angiotensin II 
to prevent them from acting on the vessels [66].
Eprosartan, irbesartan, losartan and olmesartan 
are angiotensin II receptor blockers which appeared in 
our candidate drug list. As an angiotensin II receptor 
antagonist, eprosartan blocks the binding of angiotensin 
II to the AT1 receptor in vascular smooth muscle, among 
many other tissues.  This prompts vasodilation, a reduction 
in the secretion of vasopressin and aldosterone and 
consequently leads to the effect of blood pressure decrease. 
Irbesartan (Aprovel/Karvea/Avapro) may prevent the 
progression of nephropathy caused by type 2 diabetes, 
and reduce renal disease development in patients with 
type 2 diabetes [67]. In cancer studies, irbesartan caused 
a marked reduction in volume of colorectal cancer liver 
metastases and caused changes in tumor microvasculature 
[68]. Losartan may have a positive effect on interrupting 
progression of diabetic nephropathy and reduction of 
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renal disease progression in patients with type 2 diabetes, 
hypertension and microalbuminuria or proteinuria [69]. 
Olmesartan (Benicar/Olmecip/Olsar) is used to treat 
hypertension individually or in combination with other 
antihypertensive agents. The side effects of olmesartan 
for patients of unilateral or bilateral renal artery stenosis 
include increased serum creatinine or blood urea nitrogen. 
In 2011, a U.S. Food and Drug Administration safety 
review concluded that the benefits of Benical (olmesartan) 
as an antihypertensive agent continue to outweigh its 
potential risk [70].
Eprosartan, irbesartan, losartan and olmesartan 
were identified as significant drugs from connectivity 
mapping with the KRAS mutant query gene signature. 
These four drugs are known to block Type-1 angiotensin 
II receptor, encoded by the AGTR1 gene, and hence 
they are categorized as angiotensin II receptor blockers. 
As the target of these ARB drugs, AGTR1 plays a 
major role in controlling blood pressure and volume in 
the cardiovascular system through its interaction with 
angiotensin II. AGTR1 itself is not in the combined 
KRAS-MT gene signature. One possible explanation 
of the predicted ARB effects on CRCs is that ARB 
drugs may have other targets in addition to AGTR1, 
and exert their anti-cancer effects via those unknown 
targets independently of AGTR1. Alternatively, there 
may be some yet to be understood molecular mechanism 
connecting the angiotensin system with cancer 
development and progression. 
To understand why ARB anti-hypertension drugs 
might be useful for cancer treatment, one notes that 
the local renin-angiotensin system has been reported to 
promote angiogenesis and vascular proliferation through 
the expression of VEGF (vascular endothelial growth 
factor) or EGFR (epidermal growth factor receptors) 
[71, 72]. Meanwhile, inducing angiogenesis is a well-
known hallmark of cancer [73, 74], as cancer cells need 
a constant supply of nutrients and oxygen through the 
blood system to sustain their growth and proliferation. The 
tumor-associated neovasculature, generated by the process 
of angiogenesis, addresses these needs of the cancer 
cells. The facts that the ARB drugs block the angiotensin 
II receptors and affect the functionalities of the renin-
angiotensin system, point to the possibility that ARBs may 
curb the angiogenesis-promoting activities of the system, 
and consequently exert their effects on cancer cell growth 
and proliferation. The detailed molecular mechanism of 
ARBs on cancer cells is still not well understood, but 
there seems to be a good amount of evidence for the 
potential role of the local renin-angiotensin system in 
carcinogenesis [75],  and there are reports on the effect 
of angiotensin II type-1 receptor (AT1R) antagonists in 
suppressing the growth of gastric cancer cells [76] and 
preventing angiogenesis and growth of xenograft tumors 
developed by human bladder cancer cells [77]. Therefore, 
the downregulation of AT1R, eg by ARB drugs, may well 
weaken the angiogenetic and tumor-proliferative effects 
of angiotensin [78]. These are all consistent with and 
supportive of our findings.
It is interesting to note that in a recent study [22], 
Iorio et al developed a semi-supervised  iterative pipeline 
to systematically refine drug-response signatures to 
identify novel drugs that share the principal mode of 
action of some given “seed drug”, an approach that 
was successfully applied to paclitaxel, a microtubule 
stabilizing agent, as the seed compound.  This iterative 
approach could be used to dissect the disease signatures 
generated in GECM and may help to tease out the modes 
of action of the compounds in the GECM output drug list. 
The integration of this approach with our GECM process 
is beyond the scope of this current study, but nevertheless, 
it represents a line of future research which would be 
interesting to explore. 
In this study, we conducted an intensive process 
to select gene signatures and candidate compounds for 
KRAS-MT colorectal cancer using a novel approach to 
GECM. Pathway analyses were used as quality control 
and biological validation for both selected genes and drugs 
to ensure the most precise results were obtained after each 
step. Compounds identified in the connectivity mapping 
analysis include currently used CRC treatment indicating 
the power of connectivity mapping and strong connections 
established between the KRAS-MT signature and the 
drug list. Angiotensin II receptor antagonists are strong 
therapeutic candidates emerging from our connectivity 
mapping analyses, which is interestingly supported by 
other research in the field. 
To the best of our knowledge, this is the first study 
that has shown the potential of ARB drugs as specific 
therapies for KRAS-MT CRC. As enrichment methods 
can provide more objective insights into prioritizing 
and interpreting the drugs, the result that ARB drugs are 
highly enriched in the significant drug list lends strong 
motivational support to further studies investigating 
ARB drugs as potential therapies for treating KRAS-MT 
CRCs. For example, to go beyond the scope and limit of 
the current study, it would be important in future research 
to investigate these ARB drugs experimentally in KRAS-
MT model systems (cell lines and/or animal models) to 
gain in-depth mechanistic understanding of their actions 
and interactors, providing a reinforced biological and 
pharmacological basis for subsequent clinical studies. 
Such follow-up efforts will undoubtedly facilitate the 
transition from our computational findings to clinically 
validated benefits to CRC patients.  
MATERIALS AND METHODS
Datasets: Sample selection
Datasets GSE35896, GSE39084 and GSE39582 
were obtained from the Gene Expression Omnibus (GEO), 
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a global public functional data repository collecting 
enormous high-throughput functional genomics data (such 
as microarray and sequencing data) distributed freely to 
the research community. The selection of these datasets 
for inclusion in the current study was a result of querying 
the GEO database using “KRAS” and “colorectal” and 
either “GPL96” or “GPL570” as keywords, then filtered 
by GSEs (GEO Data Series) that contain patient clinical 
samples.  GPL96 and GPL570 are two gene expression 
platforms particularly useful for the gene expression 
connectivity mapping analysis in this study. GPL96 (HG-
U133A, Affymetrix Human Genome U133A Array) is 
the same microarray platform the Connectivity Map was 
based on, and GPL570 (HG-U133_Plus_2, Affymetrix 
Human Genome U133 Plus 2.0 Array) contains almost 
all the probeIDs present in GPL96. Importantly, all the 
LINCS gene expression profiles are presented in a set of 
22268 probeIDs which are present in both GPL96 and 
GPL570 platforms. Therefore, using gene expression 
data from these two platforms, no identifier conversion 
is needed and little or no information loss is involved 
in the process.  Dataset GSE35896 from Schlicker et al 
includes 29 KRAS-MT and 33 KRAS-WT totaling 62 
samples [79]. GSE39084 was from Kirzin et al’s study, 
in which they collected the information of 954 patients 
treated and followed-up for CRC at Centre Hospitalier 
Universitaire de Toulouse, France between April 1999 
and December 2005 [80]. Dataset GSE39084 includes on-
line available expression data of 70 samples (30 samples 
are KRAS-MT, 40 samples are KRAS-WT). GSE39582 
from the French national Cartes d’Identité des Tumeurs 
(CIT) program involves 750 CRC patients who underwent 
surgery between 1987 and 2007 across seven French 
research centers/hospitals [81]. We used 545 samples with 
obtainable KRAS information, comprising 217 KRAS-MT 
and 328 KRAS-WT samples. The platforms used for these 
datasets were Affymetrix HG-U133 Plus 2 containing the 
expression measurement of 54675 probes per sample. 
As an additional note here, we also browsed the TCGA 
database and found 626 CRC cases, but unfortunately 
no gene expression data with our selected microarray 
platforms (Affymetrix HG-U133 plus 2) was available 
for the CRC cases in TCGA.  Nevertheless, TCGA as a 
valuable data resource should be explored and utilized in 
future research on other types of cancers where suitable 
datasets can be found.  
Data processing and analysis
Gene expression raw data of GSE35896, GSE39084 
and GSE39582 were downloaded from the GEO website, 
extracted and read into the R environment (R version 
2.15.1). CEL files were then normalized and summarized 
using the MAS5 algorithm as implemented in the 
Bioconductor affy package, providing human readable 
gene expression data (as tabular text files) of the samples. 
To compare the gene expression of samples between 
KRAS-MT and KRAS-WT, the GEO series matrix files 
were downloaded and extracted to obtain the KRAS 
mutation status of all individual samples. The samples of 
each dataset were then grouped into a KRAS-MT and a 
KRAS-WT cluster respectively. We therefore obtained 
6 subsets of samples for our analysis. Each dataset now 
as a unit of analysis consists of two sub-datasets, one for 
KRAS-MT samples and one for KRAS-WT samples.
Gene selection
The query gene signature is a panel of genes that 
needs to be selected to serves as an input to connectivity 
mapping. These genes exhibit a significant expression 
change between the conditions of KRAS-MT and KRAS-
WT CRCs and are a representation (characteristics) of 
the biological effects of KRAS mutation on CRC. An 
unpaired two-sample t-test was carried out between the 
wild type and mutant samples of each dataset, p-value 
and fold-change for each gene were calculated. In order 
to rigorously control the false discovery rate, a stringent 
threshold p-value (alpha) = 1/n was set, where n is the total 
number of genes analyzed. As tumor samples are being 
analyzed and the comparison was carried out between 
KRAS-MT and KRAS-WT CRCs, the gene expression 
change of KRAS mutant vs  wild type was subtle, so we 
chose a slightly more inclusive threshold of 1.2 for the 
fold change filter. A gene that fulfilled these two criteria, 
namely with a p-value smaller than 1/n and a fold change 
larger than 1.2 (either up or down), was defined as a 
significant gene. The collection of significant genes from 
statistical testing of each dataset was primarily sorted in 
ascending ordering of their p-value and secondarily sorted 
in descending order by the absolute value of log ratio. 
The gene on the top of the list has the smallest p-value, 
which is the most significant gene with expression change 
between KRAS-MT and KRAS-WT groups. A sign (+) or 
(-) is added to each gene according to the direction of gene 
expression change. As a result, each gene has a sign to 
indicate if this gene is up-regulated or down-regulated in 
the KRAS-MT samples, which is crucially important for 
specifying the gene signature pattern. 
To obtain a robust significant genes list and ensure 
that we have selected genuine gene expression alteration 
across these different datasets, we bring together 
significant genes identified from each dataset to create 
a combined gene signature using a normalized ranking 
method [82]. Each significant gene has a signed score 
from each dataset as an indication of its significance and 
regulation direction, and its signed scores from all datasets 
were added to give this gene an overall score. If a gene 
regulates differently in different datasets, the scores with 
opposite signs will cancel each other to some extent and 
the total score will be reduced. This method ensures that 
genes consistently significant across different datasets and 
also with same regulation direction gain high absolute 
scores.  Genes with a non-zero overall score were selected 
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on the combined signature. The genes in the combined 
signature were then sorted in descending order by their 
absolute overall scores, so the most significant gene is on 
top of the list. In this study, 248 gene probes were included 
in the combined signature. 
KEGG and Ingenuity pathway analysis
KEGG and Ingenuity Pathway Analysis are 
additional steps to ensure that the selected genes are 
relevant to the biological condition we are investigating 
and to determine the biological relevance of the selected 
genes. KEGG pathway analysis was carried out using the 
combined gene signature as initial input. The probe IDs 
in the gene signature were mapped to Entrez gene IDs 
using the Affymetrix annotation table. Members of KEGG 
pathways were also presented as Entrez genes. An over-
representation analysis of a pathway in the gene signature 
was performed for the KEGG human pathways. Briefly, 
for each KEGG human pathway, the number of probe IDs 
in the gene signature that can be mapped to this pathway 
was assessed against a background distribution of all 
probe IDs used in the differential expression analysis. This 
background distribution specified the number probe IDs that 
can be mapped to this particular pathway and the number 
probe IDs that cannot. All the mappings were conducted via 
the Entrez gene IDs included in the Affymetrix annotation 
table. The statistical significance of the number of probe 
IDs in the gene signature mapped to this pathway was then 
calculated using a hypergeometric test. 
Following differential expression analysis and 
signature generation, identified probe IDs were also 
analyzed using QIAGEN’s Ingenuity Pathway Analysis 
(IPA, http://www.ingenuity.com, released in December 
2015). Each probe ID was mapped to its gene annotation 
and the directionality (up or down-regulated) was included 
for the significantly differentially regulated probes. The 
returned annotated gene lists were then used to generate a 
core analysis, resulting in predicted phenotype, upstream 
regulators and networks alongside functional and canonical 
pathway analyses. The results from KEGG and Ingenuity 
Pathway Analysis validated the biological relevance of our 
selected gene signature to the KRAS-MT CRCs.
Connectivity mapping procedure
As one of the key components of connectivity 
mapping, the query gene signature is the input from 
researchers and the starting point of the connectivity 
mapping procedure. The quality of gene selection shapes the 
pattern in the query signature and consequently determines 
the output drugs. When many genes are identified as 
significant from the result of statistical hypothesis testing, 
the strategy used to construct a query signature from this 
set of genes is critically important. A well-designed query 
pattern is a vital step in obtaining an accurate profile of 
the biological condition in question and ultimately getting 
valuable results from connectivity mapping.
The common method of executing connectivity 
mapping is to use one single query signature to represent a 
biological condition of interest. Researchers normally use 
the full list of significant genes as the query signature. As 
gene selection is pivotal for the final drug results, obtaining 
the best result relies on whether a query signature can 
describe the true picture of the biological condition. We 
observed that not only the gene selection but also the 
length of a query signature influences the drug results. As 
mentioned above, the normalized ranking method we used 
helps to select the most relevant genes. In order to obtain 
precise drug results from connectivity mapping with the 
selected genes, we propose a novel process for conducting 
connectivity mapping using a panel of query signatures. 
Figure 6 shows a flowchart of this procedure.
The prime purpose of this new process is to fully 
utilize the selected genes while minimizing possible 
effects of the signature length. The combined KRAS-
MT signature of CRC from our statistical analyses on 
three independent datasets includes 248 significant 
genes that passed our stringent criteria. Genes on this 
list were sorted to ensure the most significant gene is on 
the top. We created 248 derivative signatures: signature 
1 contained only the top gene; signature 2 contained the 
top 2 two genes; signature 3 the top 3 three genes, and 
so forth, with signature 248 containing the full list of 
these 248 genes. We carried out connectivity mapping 
with these 248 query gene signatures individually using 
the sscMap framework and the reference profiles of 1354 
FDA approved drugs from the LINCS database. We 
consequently obtained 248 drug lists from connectivity 
mapping as the results for these 248 derived query 
signatures. 
Drugs selection and prioritization
After connectivity mapping, each individual 
signature produced a list of significant drugs. The first few 
signatures, with small numbers of genes, had relatively 
low numbers of significant drug hits. For instance, query 
gene signature 1 had only 3 drug hits and signature 2 
had 4 drug hits. In order to identify the drugs that are 
consistently significant across the 248 lists, the significant 
drugs on each list are sorted in descending order according 
to the absolute zscore (normalized score) from sscMap. 
A normalized ranking method was also used to score the 
significant drugs in each list to ensure that the scores from 
different lists are comparable. This approach is similar 
to the ranking method we used for the combined gene 
signature. Non-significant drugs score 0, while significant 
drugs’ scores are calculated using the formula below:
Drug score = (M - i + 1)/M
where M is the total number of significant drugs 
on the list and i is the rank of the drug in the list. The 
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drug score is then signed in line with the original zscore. 
The signed scores of each drug from all lists were added 
up in the final combined drug list, where each drug has a 
sum score of 248 individual scores, one from each drug 
list. The drugs were then sorted in descending order of 
the absolute sum score. There were 286 drugs with non-
zero sum score in the combined list that may have the 
potential to treat the disease condition, and the top drug 
had a negative score of -241.5, the last drug’s score was 
-0.01 (See Supplementary File 7 for the full list of the 286 
drugs and their overall scores).
Figure 7A shows the score changes of the 
identified top 5 drugs across signatures 1 - 248. These 
drugs consistently gained high scores in the 248 drug 
lists. In addition to examining top significant drugs, 
we also looked at recurrent themes among the top 
30 candidate compounds by manually examining the 
occurrence of drugs that have been used to treat the 
same diseases or that belong to a type of classification, 
eg, targeting the same proteins or genes in their known 
mechanism of action. The most prominent drug themes 
were then selected to undergo quantitative assessment 
of their statistical significance by a hypergeometric 
test. The whole collection of 1354 drugs used in the 
GECM analysis was examined to obtain the number of 
present drugs with that particular theme (eg, targeting 
a particular gene). Consequently, the total number 
1354 and the number with the drug theme became the 
background distribution for this particular drug theme. 
The hypergeometric test was then performed on the 
occurrence of this drug theme among the top 30 candidate 
compounds under the described background distribution. 
From this analysis, we found angiotensin II receptor 
blockers (ARB drugs) were far more significantly 
enriched than the other tested themes (EGFR, ERBB2, 
or MAP2K1/2-targeting drugs) among our top 30 drugs. 
The score changes of the 4 ARBs drugs across these 248 
drug lists are shown in Figure 7B. 
Contributive genes for the antihypertensive drugs
To investigate the reasons that ARB drugs were 
selected from connectivity mapping, contributive genes 
analysis was conducted to provide in-depth information 
of the genes whose regulation was disrupted in response 
to these drugs. We used the LINCS reference gene 
expression profiles to investigate which signature genes 
contributed to the significant connections between the 
antihypertensive drugs and the KRAS-MT CRC disease 
state. We analyzed the signed ranks of the signature 
genes in these reference profiles in conjunction with 
the corresponding regulation status in the KRAS-MT 
CRC gene signature. For each drug, the mean signed 
rank for each probe, across all reference profiles for 
that drug, was calculated, and then multiplied by the 
regulation status of the corresponding probe (+1 for up-
regulation, −1 for down-regulation) in the gene signature. 
This allows the individual ’contribution’ of each probe 
towards the overall connection score to be found - those 
probes making a negative contribution are of interest 
in potentially exposing the mechanism of action of the 
particular drug under consideration. The four angiotensin 
receptor blockers (ARB), namely eprosartan, irbesartan, 
losartan and olmesartan are of particular interest. Venny, 
which is an interactive tool for comparing lists using 
Venn Diagrams with support for up to 4 sets, was used 
to analyze these contributive genes to find the overlaps 
among the four drugs [34]. 
Figure 6: A flowchart of the comprehensive procedure for gene signature creation and drug identification. The Materials 
and Methods section provides more detailed description of the key steps involved. 
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Validation against drug screen sensitivity data
Drug screen sensitivity data were obtained from 
two independent studies. The inclusion of datasets from 
these drug screen studies was guided by the availability of 
raw data as supplied in the Supplementary Information of 
these papers. In particular, we needed the KRAS mutation 
status of the cell lines in order to compare mutant versus 
wild type cell lines. We were successful in obtaining the 
KRAS mutation status data from the Seashore-Ludlow 
2015 [35] and the Garnett 2012 [38] studies, which were 
subsequently used in this work. 
The list of compounds screened in each study was 
extracted from the supplementary data of these papers. 
Then they were mapped to the LINCS compounds 
collection either through the BRD ID (Broad Institute 
compound ID) in the case of Seashore-Ludlow data, or 
by compound name or synonyms in the case of Garnett 
study. For the common set of compounds, their reference 
gene expression profiles were extracted from the LINCS 
database, and their sensitivity data were obtained from the 
corresponding study involved. The IC50 or AUC are the 
main measures of drug sensitivity in these studies. The 
smaller the IC50 or AUC values, the more sensitive the 
cell line was to the drug. 
To compare the sensitivity of KRAS MT versus WT 
CRC cells to a particular compound, the sensitivity data 
for cells identified as CRC cell lines were first extracted. 
Based on the KRAS mutation status, the CRC cell lines 
were then divided into KRAS-MT and KRAS WT groups. 
The mean IC50 or AUC values were calculated for KRAS 
MT and KRAS WT cells, respectively, and the sign of 
their difference indicated whether KRAS MT cells were 
more sensitive to that particular drug. 
Figure 7: The normalized scores of selected drugs across the 248 derived signatures. (A) for the top 5 drugs, and (B) for the 
four ARB drugs. 
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